EXACT Therapeutics (“EXACT-Tx“) is a clinical-stage biopharmaceutical company developing a novel ultrasound-mediated technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® is a unique approach to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy and immunotherapy), infectious diseases, and neurological conditions.

On the 14th of July 2020, EXACT-Tx AS was admitted to the Oslo Stock Exchange list ‘Euronext Growth’ under EXTX-ME.

For more information about the EXACT-Tx share please visit the Oslo Børs webpage.

Click here to download the Euronext Growth Market admission document.

Investor Relations Contact

John M. Edminson - CFO
EXACT Therapeutics
Email: john.edminson@exact-tx.com

FINANCIAL REPORTS AND COMPANY PRESENTATIONS

EXACT Therapeutics hosted a virtual company presentation on December 4, 2024 following the announcement of completion of private placement

EXACT Therapeutics - Company presentation

EXACT Therapeutics presentation at CMR Symphosium, Oslo Oct 8, 2024

EXACT Therapeutics presentation at ISTU 2024, Taiwan

EXACT Therapeutics presentation at DNB Healthcare conference December 14, 2023

EXACT Therapeutics presentation at BIO-Europe, Barcelona, March 18, 2024

Financial Reporting

Annual General Meetings

Extraordinary General Meeting

Summary

Investor Relations Contact